Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2024-09-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于上海赛伦生物技术股份有限公司2024年第一次临时股东大会的法律意见书
Regulatory Filings
2024-09-30 Chinese
赛伦生物：2024年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as meeting materials for the "2024 First Extraordinary General Meeting" of Shanghai SAILUN Biotechnology Co., Ltd. It contains detailed information about the meeting agenda, voting procedures, and proposals related to the election of the new board of directors and supervisory board members. The content is focused on the meeting itself and the materials provided to shareholders for the meeting. There is no financial data, earnings information, or audit content. The document is not a report but rather the materials for a shareholders' meeting, specifically an Extraordinary General Meeting (EGM). This fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings. The document length is over 5,000 characters and contains detailed meeting materials, not just an announcement or notice, so it is not RPA or RNS. Therefore, the correct classification is AGM Information (AGM-R).
2024-09-19 Chinese
赛伦生物：关于召开2024年半年度业绩暨现金分红说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about a scheduled investor meeting to discuss the company's 2024 half-year performance and cash dividend. It references the previously published 2024 half-year report but does not contain the report itself or detailed financial data. The document is short (1518 characters) and serves to inform investors about the date, time, and format of the meeting, as well as how to participate and ask questions. This fits the profile of an Investor Presentation (IP) or an announcement related to an earnings or performance briefing. However, since it is specifically about an upcoming interactive session to discuss half-year results and cash dividends, it aligns best with an Investor Presentation (IP) rather than a full Interim Report (IR) or Earnings Release (ER).
2024-09-18 Chinese
独立董事提名人声明与承诺（傅以尚）
Board/Management Information Classification · 95% confidence The document is a formal statement from the board nominating an independent director candidate, detailing the candidate's qualifications, compliance with regulatory requirements, and independence criteria. It does not contain financial data, audit information, or report results. It is not an announcement of voting results or a proxy solicitation but rather a nomination statement related to board/management changes. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on nomination and compliance statements, confirming it is not a full report or announcement of a report publication.
2024-09-13 Chinese
独立董事提名人声明与承诺（叶榅平）
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the nominee's qualifications, compliance with legal and regulatory requirements, independence criteria, and absence of adverse records. There are no financial statements, earnings data, or report attachments. The content focuses on board/management information, specifically the nomination of a board member. The document length is short (2181 characters), and it is not an announcement of a report publication but a direct statement related to board management. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-09-13 Chinese
独立董事提名人声明与承诺（刘军岭）
Board/Management Information Classification · 95% confidence The document is a formal statement from the board of Shanghai Sailun Biotechnology Co., Ltd. nominating an independent director candidate. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There are no financial statements, earnings data, or report attachments. The content focuses on board/management information, specifically the nomination of a board member. The document length is short (2262 characters), and it is not an announcement of a report publication or certification. Therefore, the document fits best under Board/Management Information (MANG).
2024-09-13 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.